Malignant peritoneal mesothelioma revealed by episodes of recurrent spontaneous peritonitis;MESOTHELIOME PERITONEAL REVELE PAR DES EPISODES DE PERITONITE SPONTANEE A REPETITION

Gastroenterologie Clinique et Biologique

Volumn 20, Issue 1, 1996, Pages 99-102

  Fayemendy, Laurent ^a   Tulliez, Micheline ^a   Uzzan, Éric ^a   Abelanet, René ^a   Chaussade, Stanislas ^a   Couturier, Daniel ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

asbestos; mesothelioma; peritonitis

Indexed keywords

CISPLATIN; INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PERITONEUM MESOTHELIOMA; PERITONITIS; RECURRENT DISEASE; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; FATALITY; MESOTHELIOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEUM TUMOR; RADIOGRAPHY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLECTOMY; COMBINED MODALITY THERAPY; FATAL OUTCOME; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PERITONITIS; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0030080263     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Hau T, Van Hook EJ, Simmons RL. Prognostic factors of peritoneal infections in transplant patients. Surgery 1978;84:403-6.
2. Lipsky PE, Harden JA, Shour L. Spontaneous peritonitis in systemic lupus erythematosus. JAMA 1975;232:929-34.
3. Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis. Clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 1978;89:660-5.
4. Bignon J. Overview of current issues with respect to mesothelioma. Eur Respir Rev 1993;11:74-8.
5. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural malignant mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-71.
6. Brochard P, Pairon JC, Iwatsubo Y, Bignon J. Work-related mesothelioma. Eur Respir Rev 1993;11:74-8.
7. Van Gelder T, Hoogsteden HC, Versnel MA, De Beer PH, Vandenbroucke JP, Planteydt HT. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989;43:222-7.
8. Borow M, Conston A, Livornese L. Mesothelioma following exposure to asbestos: a review of 72 cases. Chest 1973;64:641-6.
9. Martensson G, Thylen A, Lindqvist U, Hjerpe A. The sensitivity of hyaluran analysis of pleural fluid in malignant mesothelioma and a comparison of different methods. Eur Respir Rev 1993;11:55-6.
10. Nurminen M, Dejmek A, Martensson G, Thylen A, Hjerpe A. Clinical utility of liquid-chromatographic effusions for hyalurinate content. Clin Chem 1994;40:777-80.
11. Chu CM, Lin SM, Peng SM, Wu CS, Liaw YF. The role of laparoscopy in the evaluation of ascites of unknown origin. Gastrointest Endosc 1994;40:285-9.
12. Wright WE, Shenvin RP. Histological types of malignant mesothelioma and asbestos exposure. Br J Ind Med 1984;41:514-7.
13. Daya D, McCaughey WTE. Well-differentiated papillary mesothelioma of the peritoneum. Cancer 1990;65:292-6.
14. Galateau F, Letourneux M, Auriault ML, Raffaeli C, Legendre C, Gignoux M, et al. Value of immunohistochemical analysis in the differential diagnosis of peritoneal mesothelioma: a study of 20 peritoneal mesotheliomas and 10 peritoneal tumours. Eur Respir Rev 1993;11:38-40.
15. Rogoff EE, Hilaris BS, Huvos AG. Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer 1973;32:656-64.
16. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993;11:1559-65.
17. Dirix LY, Van Meerbeecck J, Schrijvers D, Corthouts B, Prove A, Van Marck E, et al. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 1994;5:653-5.
18. Bowman RV, Manning LS, Davis MR, Robinson BWS. Chemosensitivity and cytokine sensitivity of malignant mesothelioma. Cancer Chemother Pharmacol 1991;28:420-6.
19. Zeng L, Monnet I, Brochard P. In vitro effects of recombinant human interferon gamma on the proliferation of human mesothelioma cell lines. J Interferon Res 1991;11:5111-4.